DiaMedica Completes FDA Pre-IND Meeting for DM199 Study
DiaMedica Therapeutics announced the completion of a productive pre-IND meeting with the FDA for a planned study evaluating DM199 in preeclampsia. The company said minutes from the meeting affirmed the FDA's request for one additional non-clinical study in a rabbit model, with results expected by Q2 2026. DiaMedica also noted that in an ongoing Phase 2 investigator-sponsored trial in South Africa, over 30 women have been dosed, with interim data showing encouraging safety and efficacy signals.
